SLSBio(Specialty Lab Solution Bio)

At a glance

SLSBio(Specialty Lab Solution Bio) filed 32 disclosures in the last 12 months, including 1 m&a. The most recent key filing was on Nov 3.

Revenue for 2025 was ₩4B, down 52.4% on 2024. It made an operating loss of ₩4.1B. Debt was 47% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩2.3B and operating loss of ₩1.8B.

The 2025 annual report lists 63 employees with an average tenure of 2 years and average pay of ₩35.7M, #1800 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩49.6M each on average. It paid no cash dividend for 2025. 이영태 and related parties held 39.93% at year end.

From the 2025 annual report

Staff: 63 (25 men, 38 women), of whom 4 on fixed-term contracts. Total pay for the year: ₩2.3B. Directors and auditors: 5, paid ₩248.2M in total.

No cash dividend was paid for 2025.

Largest shareholder

이영태 holds 15.53%; with 4 related parties the group holds 39.93% of common shares at year end (from 39.85% at the start of the year).

Auditor: 정진세림회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary